Bausch Health Companies (BHC) PT Lowered to $27 at Barclays
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts BHC Hot Sheet
Price: $8.91 +28.76%
Rating Summary:
11 Buy, 15 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 27 | New: 16
Rating Summary:
11 Buy, 15 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 27 | New: 16
Join SI Premium – FREE
Barclays analyst Balaji Prasad lowered the price target on Bausch Health Companies (NYSE: BHC) to $27.00 (from $29.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Bausch Health Companies (BHC) PT Raised to $8 at Jefferies
- Kymera Therapeutics (KYMR) PT Raised to $140 at Oppenheimer
- Boeing (BA) PT Lowered to $240 at Freedom Broker
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
